This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OPNT Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Opiant Pharmaceuticals Stock (NASDAQ:OPNT) 30 days 90 days 365 days Advanced Chart Remove Ads Get Opiant Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$20.03▼$21.1052-Week Range N/AVolume562,700 shsAverage Volume77,920 shsMarket Capitalization$108.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOpiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.Read More… Remove Ads Receive OPNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address OPNT Stock News HeadlinesMovers From YesterdayOctober 10, 2024 | benzinga.comCNFinance Hldgs (NYSE:CNF) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.April 3, 2025 | Weiss Ratings (Ad)Hikma Pharmaceuticals PLC ADR (HKMPY)April 18, 2024 | investing.comIonis PharmaceuticalsJanuary 31, 2024 | forbes.comUPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdosesMay 24, 2023 | msn.comREFILE-US FDA approves Opiant's overdose reversal sprayMay 23, 2023 | msn.comIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science PortfolioMarch 3, 2023 | msn.comSee More Headlines OPNT Stock Analysis - Frequently Asked Questions How were Opiant Pharmaceuticals' earnings last quarter? Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) released its earnings results on Thursday, November, 11th. The technology company reported $0.56 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.41. The technology company had revenue of $16.34 million for the quarter, compared to analyst estimates of $12.45 million. Opiant Pharmaceuticals had a negative net margin of 147.90% and a negative trailing twelve-month return on equity of 97.03%. What other stocks do shareholders of Opiant Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Opiant Pharmaceuticals investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and AcelRx Pharmaceuticals (ACRX). Company Calendar Last Earnings11/11/2021Today4/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OPNT CIK1108924 Webwww.opiant.com Phone(310) 598-5410Fax917-322-2105Employees37Year Founded2009Profitability EPS (Most Recent Fiscal Year)($6.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.01 million Net Margins-147.90% Pretax Margin-147.84% Return on Equity-97.03% Return on Assets-59.66% Debt Debt-to-Equity Ratio0.60 Current Ratio5.48 Quick Ratio5.48 Sales & Book Value Annual Sales$47.78 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow24.75 Book Value$9.92 per share Price / BookN/AMiscellaneous Outstanding Shares5,270,000Free Float3,865,000Market Cap$108.83 million OptionableNot Optionable Beta0.84 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:OPNT) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opiant Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opiant Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.